Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commissioner Pick OK With Kennedy, Thompson Says; Bush Nod Awaited

This article was originally published in The Gray Sheet

Executive Summary

Virginia Tech Center for Food & Nutrition Policy Director Lester Crawford, DVM/PhD, may represent the Bush administration's last chance to get an FDA commissioner nominated this year.
Advertisement

Related Content

FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent
FDA Commissioner McClellan? HHS’ Thompson Says Nomination Is Imminent
HHS Secretary Thompson Secures FDA Spot For Candidate Crawford
HHS Secretary Thompson Secures FDA Spot For Candidate Crawford
Crawford out of the woods?
Crawford out of the woods?
HHS Public Health Appointment Could Reduce Pressure For FDA Nominee
HHS Public Health Appointment Could Reduce Pressure For FDA Nominee
FDA Plays Musical Chairs In Commissioner's Office: Hot Seat Remains Open
FDA Plays Musical Chairs In Commissioner's Office: Hot Seat Remains Open
Advertisement
UsernamePublicRestriction

Register

MT015459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel